Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in germany

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Van Der Linden, Mark ^a   Falkenhorst, Gerhard ^b   Perniciaro, Stephanie ^a   Imöhl, Matthias ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; RNA 16S;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIUM ISOLATE; CHILD; DRUG EFFECT; FEMALE; GERMANY; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION; VERY ELDERLY; YOUNG ADULT; BACTERIAL GENE; CLASSIFICATION; GENETICS; IMMUNOLOGY; IMMUNOSURVEILLANCE; MICROBIOLOGY; PNEUMOCOCCAL INFECTIONS; PREVENTIVE HEALTH SERVICE; SEROTYPING;

STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, BACTERIAL; GERMANY; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNOLOGIC SURVEILLANCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RNA, RIBOSOMAL, 16S; SEROGROUP; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84938895447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131494     Document Type: Article

References (30)

1. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec. 2007; 82(12):93-104. Epub 2007/03/27. PMID: 17380597.
2. Le Polain de Waroux O, Flasche S, Prieto-Merino D, Edmunds WJ. Age-dependent prevalence of nasopharyngeal carriage of streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysis. PLoS One. 2014; 9(1):e86136. doi: 10.1371/journal.pone.0086136 PMID: 24465920; PubMed Central PMCID: PMC3900487.
3. Almeida ST, Nunes S, Santos Paulo AC, Valadares I, Martins S, Breia F, et al. Low prevalence of pneumococcal carriage and high serotype and genotype diversity among adults over 60 years of age living in Portugal. PLoS One. 2014; 9(3):e90974. doi: 10.1371/journal.pone.0090974 PMID: 24604030; PubMed Central PMCID: PMC3946249.
4. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012; 11(7):841-55. doi: 10.1586/erv.12.53 PMID: 22913260.
5. Weinberger DM, Trzcinski K, Lu YJ, Bogaert D, Brandes A, Galagan J, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS pathogens. 2009; 5(6):e1000476. doi: 10.1371/journal.ppat.1000476 PMID: 19521509; PubMed Central PMCID: PMC2689349.
6. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines. 2011; 10(8):1143-67. Epub 2011/08/04. doi: 10.1586/erv.11.99 PMID: 21810065.
7. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003; 348(18):1737-46. Epub 2003/05/02. doi: 10.1056/NEJMoa022823348/18/1737 [pii]. PMID: 12724479.
8. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites. PLoS Med. 2013; 10(9):e1001517. doi: 10.1371/journal.pmed.1001517 PMID: 24086113; PubMed Central PMCID: PMC3782411.
9. Klugman KP. Herd protection induced by pneumococcal conjugate vaccine. The Lancet Global health. 2014; 2(7):e365-6. doi: 10.1016/S2214-109X(14)70241-4 PMID: 25103373.
10. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011; 378(9807):1962-73. doi: 10.1016/S0140-6736(10)62225-8 PMID: 21492929; PubMed Central PMCID: PMC3256741.
11. Ständige Impfkommission (STIKO). Empfehlungen der Ständigen Impfkommission (STIKO) am RKI (Stand Juli 2006):Begründungen zur allgemeinen Empfehlung der Impfung gegen Pneumokokkenund Meningokokken im Säuglings- und Kindesalter. Epidemiol Bull. 2006; (31):255-60.
12. (STIKO) S. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2014. Epidemiol Bull. 2014; (34):305-39.
13. Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009; 27(31):4136-41. Epub 2009/05/02. S0264-410X(09)00611-2 [pii] doi: 10.1016/j.vaccine.2009.04.057 PMID: 19406190.
14. Ruckinger S, van der Linden M, Reinert RR, von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method. Vaccine. 2010. Epub 2010/06/16. S0264-410X(10)00697-3 [pii] doi: 10.1016/j.vaccine.2010.05.021 PMID: 20546832.
15. Weiss S, Falkenhorst G, van der Linden M, Imohl M, von Kries R. Impact of 10- and 13-valent pneumococcal conjugate vaccines on incidence of invasive pneumococcal disease in children aged under 16 years in Germany, 2009 to 2012. Euro Surveill. 2015; 20(10):21057. PMID: 25788255.
16. Theidel U, Braem A, Ruckinger S. [Determination of vaccination quotas for pneumococcal conjugate vaccine in children on the basis of routine data of the statutory health insurance]. Gesundheitswesen. 2013; 75(5):309-16. doi: 10.1055/s-0032-1321747 PMID: 23073984.
17. Poethko-Muller C, Schmitz R. [Vaccination coverage in German adults: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013; 56(5-6):845-57. doi: 10.1007/s00103-013-1693-6 PMID: 23703506.
18. van der Linden M, von Kries, R, Imöhl, M, Rückinger, S, Reinert, Rr. Increased disease awareness after onset of a national immunization program with 7-valent pneumococcal conjugate vaccine. 7th International Symposium on Pneumococci & Pneumococcal Diseases ISPPD; Tel Aviv, Israel2010.
19. Oliver MB, van der Linden MP, Kuntzel SA, Saad JS, Nahm MH. Discovery of Streptococcus pneumoniae Serotype 6 Variants with Glycosyltransferases Synthesizing Two Differing Repeating Units. J Biol Chem. 2013; 288(36):25976-85. doi: 10.1074/jbc.M113.480152 PMID: 23897812; PubMed Central PMCID: PMC3764802.
20. van der Linden M, Weiss S, Falkenhorst G, Siedler A, Imohl M, von Kries R. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine. 2012; 30(40):5880-5. doi: 10.1016/j.vaccine.2012.06.068 PMID: 22771186.
21. Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a0020literature review. Advances in therapy. 2013; 30(2):127-51. doi: 10.1007/s12325-013-0007-6 PMID: 23397399.
22. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014; 14(9):839-46. doi: 10.1016/S1473-3099(14)70822-9 PMID: 25042756.
23. Levy C, Varon E, Picard C, Bechet S, Martinot A, Bonacorsi S, et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France. Pediatr Infect Dis J. 2014; 33(12):1216-21. doi: 10.1097/INF.0000000000000451 PMID: 25037044.
24. Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013; 31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032 PMID: 24176490.
25. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8):1066-73. doi: 10.1093/cid/ciu524 PMID: 25034421.
26. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010; 28(26):4249-59. Epub 2010/04/27. S0264-410X(10)00513-X [pii] doi: 10.1016/j.vaccine.2010.04.020 PMID: 20416266.
27. van der Linden M, Reinert RR, Kern WV, Imohl M. Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children. BMC Infect Dis. 2013; 13:70. Epub 2013/02/07. 1471-2334-13-70 [pii] doi: 10.1186/1471-2334-13-70 PMID: 23384407.
28. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Ped Inf Dis J. 2013; 32(3):203-7.
29. Liyanapathirana V, Nelson EA, Ang I, Subramanian R, Ma H, Ip M. Emergence of serogroup 15 Streptococcus pneumoniae of diverse genetic backgrounds following the introduction of pneumococcal conjugate vaccines in Hong Kong. Diagn Microbiol Infect Dis. 2015; 81(1):66-70. doi: 10.1016/j.diagmicrobio.2014.09.028 PMID: 25445117.
30. Camilli R, Spencer BL, Moschioni M, Pinto V, Berti F, Nahm MH, et al. Identification of Streptococcus pneumoniae serotype 11E, serovariant 11Av and mixed populations by high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and flow cytometric serotyping assay (FCSA). PLoS One. 2014; 9(6):e100722. doi: 10.1371/journal.pone.0100722 PMID: 24967818; PubMed Central PMCID: PMC4072641.